AC
ERNA icon

Armistice Capital’s Eterna Therapeutics ERNA Stock Holding History

Armistice Capital’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-148
Closed -$274K – 207
2022
Q3 		$274K Sell
148
-431
-74% -$1.49M ﹤0.01% 159
2022
Q2 		$2.25K Sell
579
-154
-21% -$1.11M 0.04% 114
2022
Q1 		$11.3M Buy
+733
New +$13.9M 0.22% 71

Other funds holding ERNA

NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Armistice Capital's ERNA Position: Q4 2022 in Review

Armistice Capital sold out of Eterna Therapeutics (ERNA) in Q4 2022, closing a stake of 148 shares — an estimated $274K sold.

Armistice Capital first reported a position in ERNA in Q1 2022 and held it in 3 quarters. The position peaked at $11.3M in Q1 2022. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

  • Armistice Capital reported no remaining Eterna Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Armistice Capital sold 148 Eterna Therapeutics shares in Q4 2022, an estimated $274K.
  • Armistice Capital first reported a position in Eterna Therapeutics in Q1 2022 and held it in 3 quarters.
  • Armistice Capital's Eterna Therapeutics position peaked at $11.3M in Q1 2022.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2022.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.